Bicycle Therapeutics plc

14.40+0.8800+6.51%Vol 464.61K1Y Perf -53.31%
Nov 30th, 2023 16:00 DELAYED
BID13.50 ASK16.25
Open14.50 Previous Close13.52
Pre-Market- After-Market14.40
 - -  - -%
Target Price
54.57 
Analyst Rating
Strong Buy 1.23
Potential %
278.96 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★+     53.82
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
8.88 
Earnings Rating
Strong Buy
Market Cap610.87M 
Earnings Date
2nd Nov 2023
Alpha0.01 Standard Deviation0.19
Beta0.82 

Today's Price Range

14.3115.36

52W Range

12.5433.49

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
4.05%
1 Month
-6.19%
3 Months
-35.19%
6 Months
-40.74%
1 Year
-53.31%
3 Years
-29.31%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCYC14.400.88006.51
AAPL189.910.54000.29
GOOG133.91-2.4900-1.83
MSFT378.73-0.1200-0.03
XOM102.740.40000.39
WFC44.590.81001.85
JNJ154.662.55001.68
FB196.640.99000.51
GE121.802.94002.47
JPM156.081.76001.14
Financial StrengthValueIndustryS&P 500US Markets
9.00
9.20
0.12
0.15
-29.70
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-659.80
-641.80
-464.40
-
RevenueValueIndustryS&P 500US Markets
11.28M
0.38
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-1.06-1.26-18.87
Q02 2023-1.10-1.41-28.18
Q01 2023-1.06-1.30-22.64
Q04 2022-1.06-1.014.72
Q03 2022-0.98-0.962.04
Q02 2022-0.82-0.90-9.76
Q01 2022-0.70-0.93-32.86
Q04 2021-0.60-0.63-5.00
Earnings Per EndEstimateRevision %Trend
12/2023 QR-1.239.56Positive
12/2023 FY-5.27-0.38Negative
3/2024 QR-1.2112.95Positive
12/2024 FY-5.566.55Positive
Next Report Date-
Estimated EPS Next Report-1.06
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume464.61K
Shares Outstanding42.42K
Shares Float1.88M
Trades Count4.96K
Dollar Volume6.86M
Avg. Volume300.53K
Avg. Weekly Volume194.10K
Avg. Monthly Volume391.48K
Avg. Quarterly Volume316.01K

Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 14.4 per share at the end of the most recent trading day (a 6.51% change compared to the prior day closing price) with a volume of 464.61K shares and market capitalization of 610.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.

The one-year performance of Bicycle Therapeutics plc stock is -53.31%, while year-to-date (YTD) performance is -51.35%. BCYC stock has a five-year performance of %. Its 52-week range is between 12.54 and 33.49, which gives BCYC stock a 52-week price range ratio of 8.88%

Bicycle Therapeutics plc currently has a PE ratio of -9.20, a price-to-book (PB) ratio of 3.22, a price-to-sale (PS) ratio of 79.58, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -30.75%, a ROC of -37.45% and a ROE of -46.42%. The company’s profit margin is -%, its EBITDA margin is -641.80%, and its revenue ttm is $11.28 Million , which makes it $0.38 revenue per share.

Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.06 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1.23), with a target price of $54.57, which is +278.96% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bicycle Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.40, ATR14 : 1.16, CCI20 : 29.95, Chaikin Money Flow : -0.15, MACD : -0.88, Money Flow Index : 40.79, ROC : 8.35, RSI : 45.08, STOCH (14,3) : 58.13, STOCH RSI : 1.00, UO : 43.63, Williams %R : -41.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Alistair Milnes (Sold 2 248 shares of value $61 773 ), Crockett Nigel (Sold 3 141 shares of value $81 933 ), Dominic Smethurst (Sold 1 801 shares of value $52 337 ), Keen Nicholas (Sold 2 744 shares of value $73 410 ), Kevin Lee (Sold 7 486 shares of value $205 729 ), Lee H. Kalowski (Sold 2 191 shares of value $60 681 ), Lee Kevin (Sold 10 454 shares of value $272 729 ), Michael Skynner (Sold 2 248 shares of value $61 773 ), Milnes Alistair (Sold 3 141 shares of value $81 933 ), Nicholas Keen (Sold 2 136 shares of value $59 536 ), Nigel Crockett (Sold 2 248 shares of value $61 773 ), Skynner Michael (Sold 3 141 shares of value $81 933 ), Smethurst Dominic (Sold 1 801 shares of value $52 337 ), Thompson Travis Alvin (Sold 61 shares of value $1 531 ), Travis Alvin Thompson (Sold 54 shares of value $1 080 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (84.62 %)
11 (84.62 %)
10 (76.92 %)
Moderate Buy
1 (7.69 %)
1 (7.69 %)
1 (7.69 %)
Hold
1 (7.69 %)
1 (7.69 %)
2 (15.38 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.23
Strong Buy
1.23
Strong Buy
1.38

Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.

CEO: Kevin Lee

Telephone: +44 1223261503

Address: B900, Babraham Research Campus, Cambridge CB22 3AT, , GB

Number of employees: 81

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

65%35%

Bearish Bullish

64%36%

 

TipRanks News for BCYC

Tue, 12 Sep 2023 04:25 GMT Bicycle Therapeutics (BCYC) Gets a Buy from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits